(Q39459728)

12 September 2017

title

Antiproliferative effects of ester- and amide-functionalized rhizoxin derivatives (English)

1 reference

12 September 2017

5

1 reference

12 September 2017

2

Kirstin Scherlach

1 reference

12 September 2017

Björn Kusebauch

1

1 reference

12 September 2017

Heike Kirchner

series ordinal

3

1 reference

12 September 2017

Hans-Martin Dahse

series ordinal

4

1 reference

12 September 2017

publication date

25 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

6

1 reference

12 September 2017

issue

11

1 reference

12 September 2017

page(s)

1998-2001

1 reference

Rhizoxin binding to tubulin at the maytansine-binding site

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Studies on macrocyclic lactone antibiotics. VII Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Fungal phytotoxins as mediators of virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Pathogenic fungus harbours endosymbiotic bacteria for toxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Burkholderia rhizoxinica sp. nov. and Burkholderia endofungorum sp. nov., bacterial endosymbionts of the plant-pathogenic fungus Rhizopus microsporus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

A gene cluster encoding rhizoxin biosynthesis in "Burkholderia rhizoxina", the bacterial endosymbiont of the fungus Rhizopus microsporus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Antimitotic rhizoxin derivatives from a cultured bacterial endosymbiont of the rice pathogenic fungus Rhizopus microsporus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Polyketide-chain branching by an enzymatic Michael addition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Evolution of host resistance in a toxin-producing bacterial-fungal alliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Antimitotic agents: chemistry and recognition of tubulin molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Simple Method for the Esterification of Carboxylic Acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Synthesis and characterization of novel 1,2,4-triazine derivatives with antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Botryorhodines A-D, antifungal and cytotoxic depsidones from Botryosphaeria rhodina, an endophyte of the medicinal plant Bidens pilosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Folate-targeted chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

Molecular basis for determining the sensitivity of eucaryotes to the antimitotic drug rhizoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

inferred from DOI database lookup

7 January 2021

based on heuristic

A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

inferred from DOI database lookup

7 January 2021

based on heuristic

Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100319

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201100319

1 reference

12 September 2017

1 reference